0968-0896
Semimonthly
No
1464-3391
BIOORGAN MED CHEM
1993
658
ENGLAND
http://www.sciencedirect.com/science/journal/09680896
約1.9個(gè)月審稿時(shí)間
3區(qū)中科院分區(qū)
66%平均錄用比例
2.802影響因子
生化與分子生物學(xué)小學(xué)科
《生物有機(jī)與藥物化學(xué)》發(fā)表了關(guān)于化學(xué)與生物學(xué)界面上分子相互作用各方面的顯著意義和及時(shí)性的完整研究報(bào)告,并發(fā)表了評論文章。該雜志發(fā)表了關(guān)于藥物化學(xué)、化學(xué)生物學(xué)和藥物發(fā)現(xiàn)與設(shè)計(jì)的實(shí)驗(yàn)結(jié)果的報(bào)告,強(qiáng)調(diào)了這些領(lǐng)域新的和新出現(xiàn)的進(jìn)展和概念。這本雜志的目的是促進(jìn)人們更好地了解生命過程的分子水平、活生物體以及它們與化學(xué)試劑的相互作用。期刊歡迎發(fā)表以下論文:已建立或新的疾病靶點(diǎn)的藥物化學(xué)和相關(guān)生物學(xué)(包括靶點(diǎn)識別和確認(rèn));發(fā)現(xiàn)、設(shè)計(jì)或優(yōu)化有效新化合物或生物制劑的報(bào)告;利用體外和體內(nèi)模型分析和討論與藥物設(shè)計(jì)和作用相關(guān)的結(jié)構(gòu)-活性關(guān)系和藥理學(xué)問題,包括在與實(shí)驗(yàn)數(shù)據(jù)密切相關(guān)時(shí)使用計(jì)算技術(shù);“一流”新型治療化合物的報(bào)道;顯著提高生物機(jī)制知識的化學(xué)生物學(xué)或生物有機(jī)/生物無機(jī)化學(xué);以化學(xué)為基礎(chǔ),對醫(yī)學(xué)或生物學(xué)有重大影響的方法學(xué)進(jìn)展;病理生理疾病狀態(tài)生物治療的制備與檢測;特定治療靶向材料的開發(fā)。所有手稿將由獨(dú)立專家在編輯初步評估后進(jìn)行嚴(yán)格的同行評審。請注意,BMC不適合直接報(bào)告增量預(yù)付款。最重要的是,無論工作的確切領(lǐng)域是什么,合理的基礎(chǔ)和合理的基本假設(shè)的提出都是特別重要的。
http://ees.elsevier.com/bmc/
Bioorganic & Medicinal Chemistry publishes complete accounts of research of outstanding significance and timeliness on all aspects of molecular interactions at the interface of chemistry and biology, together with critical review articles. The journal publishes reports of experimental results in medicinal chemistry, chemical biology and drug discovery and design, emphasizing new and emerging advances and concepts in these fields. The aim of the journal is to promote a better understanding at the molecular level of life processes, and living organisms, as well as the interaction of these with chemical agents.The Journal welcomes papers on:the medicinal chemistry and associated biology (including target identification and validation) of established or new disease targetsthe reporting of the discovery, design or optimization of potent new compounds or biological agentsthe analysis and discussion of structure-activity relationships and pharmacological issues relevant to drug design and action using in vitro and in vivo models, including the use of computational techniques when closely linked to experimental datathe reporting of "first-in-class" new therapeutic compoundsthe chemical biology or bioorganic/bioinorganic chemistry that significantly advances knowledge of a biological mechanismmethodological advances that are chemistry-based and which significantly impact on medicine or biologythe preparation and examination of biotherapeutics for the treatment of pathophysiological disease statesthe development of materials for specific therapeutic targetingAll manuscripts will be rigorously peer-reviewed by independent experts following an initial assessment by the Editors. Please note that BMC is not suitable for straightforward reports of incremental advances. Above all the presentation of a rational basis and a sound underlying hypothesis for the work is of particular importance, whatever its exact field.
大類學(xué)科 | 分區(qū) | 小類學(xué)科 | 分區(qū) | Top期刊 | 綜述期刊 |
醫(yī)學(xué) | 3區(qū) | CHEMISTRY, ORGANIC 有機(jī)化學(xué) BIOCHEMISTRY & MOLECULAR BIOLOGY 生化與分子生物學(xué) CHEMISTRY, MEDICINAL 藥物化學(xué) | 2區(qū) 3區(qū) 3區(qū) | 否 | 否 |
JCR分區(qū)等級 | JCR所屬學(xué)科 | 分區(qū) | 影響因子 |
Q2 | CHEMISTRY, ORGANIC | Q2 | 3.461 |
BIOCHEMISTRY & MOLECULAR BIOLOGY | Q3 | ||
CHEMISTRY, MEDICINAL | Q3 |
CiteScore | SJR | SNIP | 學(xué)科類別 | 分區(qū) | 排名 | 百分位 |
6.50 | 0.598 | 0.903 | 大類:Pharmacology, Toxicology and Pharmaceutics 小類:Pharmaceutical Science | Q1 | 35 / 171 |
79% |
大類:Pharmacology, Toxicology and Pharmaceutics 小類:Organic Chemistry | Q1 | 43 / 192 |
77% |
|||
大類:Pharmacology, Toxicology and Pharmaceutics 小類:Drug Discovery | Q2 | 41 / 154 |
73% |
|||
大類:Pharmacology, Toxicology and Pharmaceutics 小類:Biochemistry | Q2 | 139 / 425 |
67% |
|||
大類:Pharmacology, Toxicology and Pharmaceutics 小類:Clinical Biochemistry | Q2 | 39 / 115 |
66% |
|||
大類:Pharmacology, Toxicology and Pharmaceutics 小類:Molecular Medicine | Q2 | 65 / 167 |
61% |
|||
大類:Pharmacology, Toxicology and Pharmaceutics 小類:Molecular Biology | Q2 | 164 / 386 |
57% |
影響因子 | h-index | Gold OA文章占比 | 研究類文章占比 | OA開放訪問 | 平均審稿速度 |
3.461 | 142 | 5.85% | 96.80% | 未開放 | 約1.9個(gè)月 |
快速預(yù)審、投刊前指導(dǎo)、專業(yè)學(xué)術(shù)評審,對文章進(jìn)行評價(jià);
立即咨詢校對編輯、深度潤色,讓稿件符合學(xué)術(shù)規(guī)范,格式體例等標(biāo)準(zhǔn);
立即咨詢適用于語句和結(jié)構(gòu)尚需完善和調(diào)整的中文文章,確保稿件達(dá)到要求;
立即咨詢數(shù)據(jù)庫包括:期刊、文章、書籍、會議、預(yù)印書、百科全書和摘要等;
立即咨詢讓作者在期刊選擇時(shí)避免走彎路,縮短稿件被接收的周期;
立即咨詢根據(jù)目標(biāo)期刊格式要求對作者文章進(jìn)行全面的格式修改和調(diào)整;
立即咨詢幫助作者將稿件提交至目標(biāo)期刊投稿系統(tǒng),降低退稿或拒稿率;
立即咨詢按照您提供的稿件內(nèi)容,指導(dǎo)完成投稿附信(cover letter);
立即咨詢大類學(xué)科同領(lǐng)域優(yōu)質(zhì)期刊 | 大類學(xué)科 | 小類學(xué)科 | 影響因子 | 分區(qū) | ISSN |
---|---|---|---|---|---|
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 醫(yī)學(xué) | 生化與分子生物學(xué) | 6.887 | N/A | 0304-419X |
BIOORGANIC & MEDICINAL CHEMISTRY | 醫(yī)學(xué) | 生化與分子生物學(xué) | 2.802 | 3區(qū) | 0968-0896 |
Chemical Biology & Drug Design | 醫(yī)學(xué) | 生化與分子生物學(xué) | 2.256 | 4區(qū) | 1747-0277 |
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY | 醫(yī)學(xué) | 生化與分子生物學(xué) | 2.697 | N/A | 1532-0456 |
CURRENT DRUG METABOLISM | 醫(yī)學(xué) | 生化與分子生物學(xué) | 2.277 | 3區(qū) | 1389-2002 |
INFECT MED | 醫(yī)學(xué) | 生化與分子生物學(xué) | N/A | 3區(qū) | 0929-8673 |
MED ORAL PATOL ORAL | 醫(yī)學(xué) | 生化與分子生物學(xué) | N/A | N/A | 0957-9672 |
CURRENT PHARMACEUTICAL BIOTECHNOLOGY | 醫(yī)學(xué) | 生化與分子生物學(xué) | 1.516 | N/A | 1389-2010 |
CYTOKINE | 醫(yī)學(xué) | 生化與分子生物學(xué) | 3.078 | 3區(qū) | 1043-4666 |
EXPERIMENTAL AND MOLECULAR MEDICINE | 醫(yī)學(xué) | 生化與分子生物學(xué) | 4.743 | 2區(qū) | 1226-3613 |
發(fā)現(xiàn)心儀選題請?zhí)顔?/b>
獲取發(fā)表周期短、審稿速度快容易錄用的期刊